Cargando…

Effects of dexamethasone coadministered with oseltamivir on the pharmacokinetics of oseltamivir in healthy volunteers

PURPOSE: Oseltamivir is widely used in the treatment and prophylaxis of influenza A and B viral infections. It is ingested as an oral prodrug that is rapidly metabolized by carboxylesterase 1 (CES1) to its active form, oseltamivir carboxylate. Dexamethasone is also used in the treatment of acute res...

Descripción completa

Detalles Bibliográficos
Autores principales: Jang, Kyungho, Kim, Min-Kyoung, Oh, Jaeseong, Lee, SeungHwan, Cho, Joo-Youn, Yu, Kyung-Sang, Choi, Tai Kiu, Lee, Sang-Hyuk, Lim, Kyoung Soo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352149/
https://www.ncbi.nlm.nih.gov/pubmed/28331290
http://dx.doi.org/10.2147/DDDT.S124307
_version_ 1782514896526639104
author Jang, Kyungho
Kim, Min-Kyoung
Oh, Jaeseong
Lee, SeungHwan
Cho, Joo-Youn
Yu, Kyung-Sang
Choi, Tai Kiu
Lee, Sang-Hyuk
Lim, Kyoung Soo
author_facet Jang, Kyungho
Kim, Min-Kyoung
Oh, Jaeseong
Lee, SeungHwan
Cho, Joo-Youn
Yu, Kyung-Sang
Choi, Tai Kiu
Lee, Sang-Hyuk
Lim, Kyoung Soo
author_sort Jang, Kyungho
collection PubMed
description PURPOSE: Oseltamivir is widely used in the treatment and prophylaxis of influenza A and B viral infections. It is ingested as an oral prodrug that is rapidly metabolized by carboxylesterase 1 (CES1) to its active form, oseltamivir carboxylate. Dexamethasone is also used in the treatment of acute respiratory distress syndrome, a severe complication of influenza; however, its influence on the pharmacokinetics (PK) of oseltamivir is controversial. The aim of this study was to investigate the effects of coadministering oseltamivir and dexamethasone on the PK of oseltamivir in healthy volunteers. METHODS: An open-label, two-period, one-sequence, multiple-dose study was conducted in 19 healthy male volunteers. Oseltamivir (75 mg) was orally administered on Day 1 and Day 8, and dexamethasone (1.5 mg) was administered once daily from Day 3 to Day 8. Serial blood and urine samples were collected for PK analysis of oseltamivir and oseltamivir carboxylate on Day 1 and Day 8. Oseltamivir and oseltamivir carboxylate concentrations in plasma and urine were determined using liquid chromatography–tandem mass spectrometry. RESULTS: Area under the plasma concentration–time curve (AUC) of oseltamivir and oseltamivir carboxylate decreased after dexamethasone treatment for 6 days. The geometric mean ratio (90% confidence interval) of the metabolic ratio (oseltamivir carboxylate AUC(0–48h)/oseltamivir AUC(0–48h)) was 0.92 (0.87–0.97). The amount of unchanged oseltamivir excreted in urine increased by 14% after dexamethasone treatments. CONCLUSION: Coadministration of dexamethasone with oseltamivir slightly decreased systemic exposure to oseltamivir and oseltamivir carboxylate in healthy volunteers. This result suggests that CES1 is inhibited by dexamethasone in humans. However, coadministration of oseltamivir and dexamethasone did not appear to have a clinically relevant effect on the PK of oseltamivir; based on these results, dexamethasone can be coadministered with oseltamivir.
format Online
Article
Text
id pubmed-5352149
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-53521492017-03-22 Effects of dexamethasone coadministered with oseltamivir on the pharmacokinetics of oseltamivir in healthy volunteers Jang, Kyungho Kim, Min-Kyoung Oh, Jaeseong Lee, SeungHwan Cho, Joo-Youn Yu, Kyung-Sang Choi, Tai Kiu Lee, Sang-Hyuk Lim, Kyoung Soo Drug Des Devel Ther Original Research PURPOSE: Oseltamivir is widely used in the treatment and prophylaxis of influenza A and B viral infections. It is ingested as an oral prodrug that is rapidly metabolized by carboxylesterase 1 (CES1) to its active form, oseltamivir carboxylate. Dexamethasone is also used in the treatment of acute respiratory distress syndrome, a severe complication of influenza; however, its influence on the pharmacokinetics (PK) of oseltamivir is controversial. The aim of this study was to investigate the effects of coadministering oseltamivir and dexamethasone on the PK of oseltamivir in healthy volunteers. METHODS: An open-label, two-period, one-sequence, multiple-dose study was conducted in 19 healthy male volunteers. Oseltamivir (75 mg) was orally administered on Day 1 and Day 8, and dexamethasone (1.5 mg) was administered once daily from Day 3 to Day 8. Serial blood and urine samples were collected for PK analysis of oseltamivir and oseltamivir carboxylate on Day 1 and Day 8. Oseltamivir and oseltamivir carboxylate concentrations in plasma and urine were determined using liquid chromatography–tandem mass spectrometry. RESULTS: Area under the plasma concentration–time curve (AUC) of oseltamivir and oseltamivir carboxylate decreased after dexamethasone treatment for 6 days. The geometric mean ratio (90% confidence interval) of the metabolic ratio (oseltamivir carboxylate AUC(0–48h)/oseltamivir AUC(0–48h)) was 0.92 (0.87–0.97). The amount of unchanged oseltamivir excreted in urine increased by 14% after dexamethasone treatments. CONCLUSION: Coadministration of dexamethasone with oseltamivir slightly decreased systemic exposure to oseltamivir and oseltamivir carboxylate in healthy volunteers. This result suggests that CES1 is inhibited by dexamethasone in humans. However, coadministration of oseltamivir and dexamethasone did not appear to have a clinically relevant effect on the PK of oseltamivir; based on these results, dexamethasone can be coadministered with oseltamivir. Dove Medical Press 2017-03-09 /pmc/articles/PMC5352149/ /pubmed/28331290 http://dx.doi.org/10.2147/DDDT.S124307 Text en © 2017 Jang et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Jang, Kyungho
Kim, Min-Kyoung
Oh, Jaeseong
Lee, SeungHwan
Cho, Joo-Youn
Yu, Kyung-Sang
Choi, Tai Kiu
Lee, Sang-Hyuk
Lim, Kyoung Soo
Effects of dexamethasone coadministered with oseltamivir on the pharmacokinetics of oseltamivir in healthy volunteers
title Effects of dexamethasone coadministered with oseltamivir on the pharmacokinetics of oseltamivir in healthy volunteers
title_full Effects of dexamethasone coadministered with oseltamivir on the pharmacokinetics of oseltamivir in healthy volunteers
title_fullStr Effects of dexamethasone coadministered with oseltamivir on the pharmacokinetics of oseltamivir in healthy volunteers
title_full_unstemmed Effects of dexamethasone coadministered with oseltamivir on the pharmacokinetics of oseltamivir in healthy volunteers
title_short Effects of dexamethasone coadministered with oseltamivir on the pharmacokinetics of oseltamivir in healthy volunteers
title_sort effects of dexamethasone coadministered with oseltamivir on the pharmacokinetics of oseltamivir in healthy volunteers
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352149/
https://www.ncbi.nlm.nih.gov/pubmed/28331290
http://dx.doi.org/10.2147/DDDT.S124307
work_keys_str_mv AT jangkyungho effectsofdexamethasonecoadministeredwithoseltamivironthepharmacokineticsofoseltamivirinhealthyvolunteers
AT kimminkyoung effectsofdexamethasonecoadministeredwithoseltamivironthepharmacokineticsofoseltamivirinhealthyvolunteers
AT ohjaeseong effectsofdexamethasonecoadministeredwithoseltamivironthepharmacokineticsofoseltamivirinhealthyvolunteers
AT leeseunghwan effectsofdexamethasonecoadministeredwithoseltamivironthepharmacokineticsofoseltamivirinhealthyvolunteers
AT chojooyoun effectsofdexamethasonecoadministeredwithoseltamivironthepharmacokineticsofoseltamivirinhealthyvolunteers
AT yukyungsang effectsofdexamethasonecoadministeredwithoseltamivironthepharmacokineticsofoseltamivirinhealthyvolunteers
AT choitaikiu effectsofdexamethasonecoadministeredwithoseltamivironthepharmacokineticsofoseltamivirinhealthyvolunteers
AT leesanghyuk effectsofdexamethasonecoadministeredwithoseltamivironthepharmacokineticsofoseltamivirinhealthyvolunteers
AT limkyoungsoo effectsofdexamethasonecoadministeredwithoseltamivironthepharmacokineticsofoseltamivirinhealthyvolunteers